Spiegel Robert J. — SEC insider filings
SEC reporting owner CIK 1492256. 56 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers the 50 most recent of 56 filings on record, filed 2021-06-17 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 40,983 shares.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 62.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| RenovoRx, Inc. (RNXT) | Director | 6 | 1 leg · 40,983 sh | — | 6 |
| GERON CORP (GERN) | Director | 29 | — | — | 31 |
| Athenex, Inc. (ATNX) | Director | 8 | — | — | 10 |
| Cyclacel Pharmaceuticals, Inc. (CYCC) | Director | 3 | — | — | 6 |
| Old Ayala, Inc (AYLA) | Director | 2 | — | — | 5 |
| Ayala Pharmaceuticals, Inc. (ADXS) | Director | 1 | — | — | 4 |
| Ernexa Therapeutics Inc. (ERNA) | Director | 1 | — | — | — |
Insider filings — Spiegel Robert J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | RenovoRx, Inc. (RNXT) | Grant/award (A): 55,924 (derivative) @ $0 | EDGAR |
| 2026-10-01 | 4 | GERON CORP (GERN) | Grant/award (A): 6,351 @ $1.23 | EDGAR |
| 2026-09-22 | 3 | Ernexa Therapeutics Inc. (ERNA) | Holdings only — no transactions reported | EDGAR |
| 2026-07-01 | 4 | GERON CORP (GERN) | Grant/award (A): 6,103 @ $1.28 | EDGAR |
| 2026-05-26 | 4 | GERON CORP (GERN) | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,243 @ $1.49 | EDGAR |
| 2026-01-05 | 4 | GERON CORP (GERN) | Grant/award (A): 5,918 @ $1.32 | EDGAR |
| 2025-10-02 | 4 | RenovoRx, Inc. (RNXT) | Grant/award (A): 47,640 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,702 @ $1.37 | EDGAR |
| 2025-07-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,540 @ $1.41 | EDGAR |
| 2025-05-22 | 4 | GERON CORP (GERN) | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4/A | GERON CORP (GERN) | Grant/award (A): 2,462 @ $3.30 · Grant/award (A): 1,916 @ $4.24 | EDGAR |
| 2025-04-02 | 4/A | GERON CORP (GERN) | Grant/award (A): 1,767 @ $4.54 | EDGAR |
| 2025-04-02 | 4/A | GERON CORP (GERN) | Grant/award (A): 2,206 @ $3.54 | EDGAR |
| 2025-04-02 | 4 | GERON CORP (GERN) | Grant/award (A): 4,913 @ $1.59 | EDGAR |
| 2025-01-02 | 4 | GERON CORP (GERN) | Grant/award (A): 2,206 @ $0 | EDGAR |
| 2024-10-02 | 4 | RenovoRx, Inc. (RNXT) | Grant/award (A): 25,099 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | GERON CORP (GERN) | Grant/award (A): 1,767 @ $0 | EDGAR |
| 2024-06-28 | 4 | GERON CORP (GERN) | Grant/award (A): 2,462 @ $0 · Grant/award (A): 1,916 @ $0 | EDGAR |
| 2024-05-10 | 4 | GERON CORP (GERN) | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | RenovoRx, Inc. (RNXT) | Purchase (P): 40,983 · Purchase (P): 40,983 (derivative) | EDGAR |
| 2024-01-03 | 4 | GERON CORP (GERN) | Grant/award (A): 3,406 @ $0 | EDGAR |
| 2023-10-02 | 4 | GERON CORP (GERN) | Grant/award (A): 3,390 @ $0 | EDGAR |
| 2023-10-02 | 4 | RenovoRx, Inc. (RNXT) | Grant/award (A): 25,099 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Grant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | GERON CORP (GERN) | Grant/award (A): 2,239 @ $0 | EDGAR |
| 2023-06-02 | 4 | GERON CORP (GERN) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-04-27 | 4 | RenovoRx, Inc. (RNXT) | Grant/award (A): 43,026 (derivative) @ $0 | EDGAR |
| 2023-04-24 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 2,300 @ $1.30 | EDGAR |
| 2023-04-03 | 4 | GERON CORP (GERN) | Grant/award (A): 3,312 @ $0 | EDGAR |
| 2023-01-23 | 4 | Ayala Pharmaceuticals, Inc. (ADXS) | Grant/award (A): 3,279 (derivative) · Grant/award (A): 2,342 (derivative) · Grant/award (A): 1,171 (derivative) · Grant/award (A): 1,171 (derivative) | EDGAR |
| 2023-01-23 | 4 | Old Ayala, Inc (AYLA) | Disposition to issuer (D): 17,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 6,250 (derivative) · Disposition to issuer (D): 6,250 (derivative) | EDGAR |
| 2023-01-17 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 16,130 @ $0.19 | EDGAR |
| 2023-01-03 | 4 | GERON CORP (GERN) | Grant/award (A): 2,970 @ $0 | EDGAR |
| 2022-10-12 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 12,453 @ $0.24 | EDGAR |
| 2022-10-03 | 4 | GERON CORP (GERN) | Grant/award (A): 3,071 @ $0 | EDGAR |
| 2022-08-30 | 4 | Athenex, Inc. (ATNX) | Option exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2022-07-21 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 4,508 @ $0.67 | EDGAR |
| 2022-07-01 | 4 | GERON CORP (GERN) | Grant/award (A): 4,637 @ $0 | EDGAR |
| 2022-06-29 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Grant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Ayala Pharmaceuticals, Inc. (AYLA) | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2022-05-11 | 4 | GERON CORP (GERN) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-04-11 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 3,989 @ $0.75 | EDGAR |
| 2022-04-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,284 @ $0 | EDGAR |
| 2022-01-03 | 4 | GERON CORP (GERN) | Grant/award (A): 5,891 @ $0 | EDGAR |
| 2021-10-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,246 @ $0 | EDGAR |
| 2021-08-05 | 4 | Athenex, Inc. (ATNX) | Grant/award (A): 8,750 (derivative) @ $0 · Grant/award (A): 8,750 (derivative) @ $0 | EDGAR |
| 2021-07-01 | 4 | GERON CORP (GERN) | Grant/award (A): 5,097 @ $0 | EDGAR |
| 2021-06-17 | 4 | Cyclacel Pharmaceuticals, Inc. (CYCC) | Grant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1492256 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs